Related Experiment Video
Updated: May 7, 2026
13:14
Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood
Published on: February 6, 2018
Antigen-specific in vitro immunization: a source for human monoclonal antibodies
Kosuke Tomimatsu1, Sanetaka Shirahata
1Faculty of Agriculture, Department of Bioscience and Biotechnology, Kyushu University, Fukuoka, Japan.
Methods in Molecular Biology (Clifton, N.J.)
|September 17, 2013
Summary
An in vitro immunization (IVI) protocol effectively generates antigen-specific immune responses in human peripheral blood mononuclear cells (PBMCs). This method enhances the production of human monoclonal antibodies for therapeutic applications.
Area of Science:
- Immunology
- Biotechnology
- Therapeutic Antibody Development
Background:
- Human monoclonal antibodies offer targeted therapeutic potential for various diseases due to their antigen specificity.
- Efficient production of these antibodies is crucial for advancing treatment strategies.
Purpose of the Study:
- To present an in vitro immunization (IVI) protocol for generating antigen-specific immune responses.
- To demonstrate the IVI protocol's efficacy in producing human monoclonal antibodies.
Main Methods:
- Utilizing an in vitro immunization (IVI) protocol on human peripheral blood mononuclear cells (PBMCs).
- Measuring antigen-specific antibody production post-immunization.
Main Results:
- The IVI protocol successfully induced antigen-specific immune responses in PBMCs.
- Increased production of antigen-specific antibodies was observed, facilitating efficient gene acquisition.
Conclusions:
- The developed IVI protocol is a valuable tool for enhancing human monoclonal antibody production.
- This method holds broad applicability for combination with display technologies to improve antibody discovery.
